Transgene

Transgene EBIT Growth

The Year-over-Year EBIT Growth of Transgene (TNG.PA) as of Nov 18, 2026 is -18.80 %. In the previous year, Year-over-Year EBIT Growth was -0.38 % — a change of 4,831.20% (lower).

EBIT Growth

-18.80 %

YoY

4,831.20%

Last updated:

Year-over-Year EBIT Growth of Transgene is 2024 -18.80 % . Year-over-Year EBIT Growth of Transgene was 2023 -0.38 % . It decreases by 4,831.20% lower compared to the previous year.

The Transgene EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
-24.82 EUR
Jan 1, 2018
126.40 EUR
Jan 1, 2019
-443.73 EUR
Jan 1, 2020
5.52 EUR
Jan 1, 2021
1.97 EUR
Jan 1, 2022
-27.11 EUR
Jan 1, 2023
-0.38 EUR
Jan 1, 2024
-18.80 EUR
The Transgene EBIT Growth history
YEAREBIT GrowthYoY
-18.80 %+4,831.20%
-0.38 %-98.59%
-27.11 %-1,478.17%
1.97 %-64.37%
5.52 %-101.24%
-443.73 %-451.06%
126.40 %-609.25%
-24.82 %-220.13%
20.66 %+15.16%
17.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Year-over-Year EBIT Growth of Transgene is -18.80 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Transgene since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Transgene

All Key Metrics — Transgene